At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 143 enrolled
Drug / intervention
IVX-A12 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Modified Double-Blind, Active Controlled Study to Characterize the Safety and Immunogenicity of IVX-A12 in Adults 60 Years of Age and Older
In Brief
A Phase 2 clinical trial evaluating IVX-A12 and Licensed RSV Vaccine for Healthy Participants. Completed, enrolled 143 participants across 5 sites.
Detailed Summary
The primary purpose of this study is to assess the immunogenicity and safety of IVX-A12 in adults 60 years of age and older.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20252026
Enrollment StartJun 2024
First PostedJul 2024
Primary CompletionJul 2024
Study CompletionDec 2024
TodayJul 2026
First PostedJul 1, 2024
Enrollment StartJun 10, 2024
Primary CompletionJul 17, 2024
Study CompletionDec 19, 2024
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 2.0 years ago
Interventions
IVX-A12biological
IVX-A12 IM injection.
Licensed RSV Vaccinebiological
Licensed RSV Vaccine (AREXVY) IM injection.